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Background: Limited access to drugs is a crucial barrier to reducing the growing impact of cancer in low- and
middle-income countries. Approaches based on drug donations or adaptive pricing strategies yield promising but
varying results across countries or programs, The Glivec International Patient Assistance Program (GIPAP) is a
program designed to provide imatinib free of charge to patients with chronic myeloid leukemia (CML) or
gastrointestinal stromal tumors (GIST). The objective of this work was to identify institutional factors associated with
enrollment and patient survival in GIPAP.
Methods: We analyzed follow-up data from 4,946 patients participating in 47 institutions within 44 countries
between 2003 and 2010. Active status in the program was considered as a proxy for survival.
Results: Presence of ≥1 hematologist or oncologist at the institution was associated with increased patient
enrollment. After adjusting for individual factors such as age (>55 years: Hazard Ratio [HR] = 1.42 [1.16; 1.73];
p = 0.001) and initial stage of disease (accelerated or blast crisis at diagnosis: HR = 4.16 [1.87; 9.25]; p < 10-4),
increased survival was found in institutions with research capabilities (HR = 0.55 [0.35; 0.86]; p = 0.01) and those with
enrollment of >5 patients/year into GIPAP (HR = 0.48 [0.35; 0.67]; p < 10-4), while a non-significant trend for
decreased survival was found for treatment at a public institution (HR = 1.32 [0.95; 1.84]; p = 0.10). The negative
impact of an accelerated form of CML was attenuated by the presence of ≥1 hematologist or oncologist at the
institution (interaction term HR = 0.43 [0.18; 0.99]; p = 0.05).
Conclusions: Application of these findings to the support and selection of institutions participating in GIPAP may
help to optimize care and outcomes for CML and GIST patients in the developing world. These results may also be
applicable to the treatment of patients with other forms of cancer, due to the overlap of infrastructure and staff
resources used to treat a variety of cancer indications. A multi-sector approach is required to address these barriers.
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The incidence of cancer is increasing globally, particu-
larly in low-and middle-income countries [1-5]. The in-
creased incidence of cancer in these countries is
essentially due to a combination of a decrease in deaths
from infectious diseases and an increase in average* Correspondence: Joseph.Saba@axiosint.com
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distribution, and reproduction in any mediumpopulation age [1,3,4]. It is estimated that the proportion
of cancers diagnosed in low- and middle-income countries
will rise over the next two decades, ultimately accounting
for approximately 70% of cases globally [1,4]. There are a
number of challenges to reducing the impact of cancer in
low- and middle-income countries, including a lack of
effective cancer surveillance and control, lack of trained
cancer specialists, lack of diagnostic and treatment
capacity, few functional cancer registries, scarce andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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equate health care, effective disease prevention policies and
health care funding [4,6]. The high cost of newer, more
targeted therapies for cancer also creates a significant barrier
to providing cancer patients in low- and middle-income
countries with the latest advances in care treatment [1,5].
The growing impact of cancer in low- and middle-
income countries calls for new approaches to preventing
and treating this disease [1]. While limited data are avail-
able for access programs that target non-communicable
diseases, the success of various efforts to increase access to
HIV therapies provides several models that may be applied
to cancer and other chronic diseases [1,5,7,8]. Such efforts
include integration of HIV care with other health and social
services, reduced and not-for-profit pricing of HIV medica-
tions, drug donations and a variety of partnerships among
national governments, non-governmental organizations
(NGOs) and pharmaceutical industries [5,9,10]. Several
innovative strategies for reducing the impact of cancer
in low- and middle-income countries have already been
implemented and are showing promise in improving ac-
cess to care and patient outcomes [6,11-15]. These efforts
include: decreasing cancer risk factors (such as tobacco
exposure), development of guidelines for establishing
national cancer programs, leveraging existing cancer
research capabilities to establish additional cancer-related
programs, establishment of national or regional referral
centers, use of telemedicine to improve access in remote
areas, increasing access to cancer screening, drug dona-
tions and adaptive pricing strategies in which patients pay
what they can afford and have the rest of their medication
costs covered by other organizations [6,11-13,16].
Glivec (imatinib), a small molecule inhibitor of the bcr-abl
tyrosine kinase that results from the Philadelphia chromo-
some (Ph+), has been shown to improve progression-
free survival in patients with Ph + chronic myeloid
leukemia (CML) [17]. The annual incidence of CML is
estimated at 0.6-2.0 people per 100,000, and the prevalence
of CML appears to be increasing, potentially due to
increased survival resulting from treatment with imatinib
[11,18,19]. Clinical studies also support the utility of
imatinib in the treatment of gastrointestinal stromal tumor
(GIST) [17]. While imatinib has been shown to improve
outcomes for CML and GIST patients, its average cost of
$2,500 to $3,500 USD per month could limit its use in low-
and middle-income countries.
The Glivec International Patient Assistance Program
(GIPAP) began in 2001 through the support of Novartis,
the manufacturer of imatinib, in conjunction with Axios
International, The Max Foundation and several other
NGOs. The program is designed to expand access
to imatinib among patients with CML or GIST. The
program has been implemented in 81 developing
countries-including 49 Least Developed Countries(LDCs) as defined by the United Nations–and reached
50,395 patients who have received Glivec through GIPAP
free of charge.
A previous study has shown that patients participating
in GIPAP are more likely to improve their phase state,
regardless of disease stage at the time of entry into the
program, and that patients in the program show high
survival rates after 2 years, comparable with data from a
randomized phase III trial [11,20,21]. The authors of this
study identified several differences between countries
with respect to the magnitude of the improvements in
the health state achieved by patients enrolled in GIPAP,
although these trends did not reach statistical significance.
This suggests that important factors nested at the national
or institutional level could influence outcomes at the
patient level. In this respect, both the overall organization
of a country’s national health system (i.e. health insurance
coverage, access to healthcare) and local characteristics,
such as research ability or public/private status of the
institutions and hospitals at which GIPAP has been
implemented could play a significant role in patient
outcomes. It is still not known if the capacity of a given
institution to enroll patients into GIPAP efficiently and
on a regular basis could be associated with better out-
comes for patients in the program.
In order to address these important questions, the
objectives of this study were to 1) describe the patients
and the institutions that participated in GIPAP, 2) assess
enrollment rates at the institutional level and identify
their possible determinants and 3) identify patient and
institutional factors associated with patient survival.
Methods
The requirements for participation in GIPAP have been
described previously [11]. Briefly, patient eligibility is deter-
mined primarily on the basis of diagnosis, as well as income/
socioeconomic status, as follows: (a) GIPAP helps patients
who are properly diagnosed with Philadelphia chromosome-
positive chronic myeloid leukemia (Ph +CML) and patients
with c-Kit (CD117)-positive inoperable and/or metastatic
malignant gastrointestinal stromal tumors (GISTs) and (b)
GIPAP provides assistance to patients who are not insured
or reimbursed, cannot pay for treatment privately, and live
in countries that have minimal reimbursement capabilities
for their condition. Based on these criteria, GIPAP may
cover all those diagnosed with CML in certain countries be-
cause of their low-income level. The program helps eligible
patients by providing imatinib free of charge, in addition to
information and referral assistance to patients, their families
and caregivers throughThe Max Foundation.
Data collection
Data from institutions participating in GIPAP have been
collected in several databases. Axios maintains an Access
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database, which captures detailed information on institu-
tions and countries where Axios programs operate. The
Max Foundation also maintains an institution, physician
and a Patient Assistance Tracking System (PATS). All
data analyses were retrospective, based on existing patient
records collected by physicians as part of the patient’s rou-
tine clinical care and transmitted to Axios and the Max
Foundation without any identifiers. Given these parameters,
an Institutional Review Board (IRB) exemption was re-
quested and received from the Western IRB. Analyses were
conducted under the authorization from Novartis and the
Max Foundation. In the present paper, data were available
only for programs managed by Axios (44/81 countries).
Consequently, programs directly managed by Novartis were
not included in the analysis.
Patients’ inclusion and quarterly follow-up data were
systematically collected for each hospital participating in
GIPAP. All individual data were initially collected by the
physicians in charge of the patients and then anonymously
transmitted to Axios and the Max foundation. Axios
actively monitored the quality of those individual data
by conducting regular audits. At the patient level,
socio-demographic and health characteristics were col-
lected, including gender, age at enrollment, initial diag-
nosis (GIST or CML, along with the stage of disease:
chronic, accelerated and blast crisis), and the hospital
at which the patient was enrolled and treated. The date
of inclusion in the cohort was the date of initial patient
approval between 2003 and 2010. The end point was
the date of the last reapproval in 2010 for active pa-
tients or the date of closure for other patients. The rea-
sons for closure were: lost to contact, clinical reason,
death, and other. The duration of follow up was mea-
sured from the date of inclusion to the end-point date
and was considered as a proxy for survival. Only pa-
tients for whom complete institutional information
was available were included in the analysis.
At the institutional level, institutions run by the govern-
ment were classified as public institutions, while hospitals
operated by non-governmental organizations (NGOs), or
private or other organizations, were classified as private
institutions. Data on core competencies related to opera-
tions research, clinical trials, and training activities were
also collected. Institutions with activity in at least one of
these competencies were classified as having institutional
research ability. Data on institutions’ technical competen-
cies were also collected and comprised Ph + chromosome
testing for CML or CD 117 testing for GIST diagnosis,
and the use of bone marrow biopsy or aspiration. Data on
the availability of hematologists or oncologists at the insti-
tutions were also collected. In addition, institutions were
stratified by location within the WHO region (Africa,
America, Eastern Europe, Pacifica and South East Asia) inorder to assess the independent role of the factors previ-
ously described, while adjusting for supranational features
shared by countries from the same WHO regions; those
features are related to health care system factors such as
the overall financial or organizational strength, and could
confound the relationship between institutional factors
and enrollment or survival.
Statistical analysis
Descriptive statistics are given as means with their
standard deviation (SD), and inter-quartile range (IQR)
for continuous variables and as percentages for categor-
ical variables. In order to assess the performance of the
included institutions regarding enrollment, we used lin-
ear mixed models entering the total number of enrolled
patients as the dependant variable, the year as the inde-
pendent variable, and the institution as a random effect
so as to account for the longitudinal structure of the
data based on yearly repeated measures. In order to
identify institutional factors associated with higher en-
rollment rates, interactions were tested between the year
and the following variables: public institution, presence
of a hematologist or oncologist, research ability, bone as-
piration capability, and location within the WHO region.
The evaluation of performance at the patient level was
performed using multivariate Cox models accounting for
the clustered structure of the data within institutions
and considering the activity status of the patient as a
proxy for survival. Thus, closure for death or clinical rea-
son was considered as the event of interest, with death de-
termined by patient being defined as “dead” at the latest
follow-up. Closure for other reasons lost to follow-up, and
active status (patient still alive at latest follow-up) at the
end of the study were analyzed as censored data. In an
alternative sensitivity analysis, closure for any reason
and lost to follow-up were also considered as events of
interest. Results from the original and alternate analyses
were similar, and the latter results are not included in
this report. The following variables were entered as pa-
tient or institutional predictors for death: age, sex, initial
phase of CML, type of institution, specialized human re-
sources at the institution (hematologist or oncologist),
research ability and the capability to perform bone
marrow biopsy or aspiration, number of physicians, en-
rollment rate (<2, [2–5], >5 patients/year), and the
WHO region. Hazard ratios (HR) were expressed with
their 95% confidence intervals. Sensitivity analyses
were systematically performed to assess if different
results were obtained when including or excluding
the programs with the highest numbers of patients
(namely, Sudan [N = 971], Uzbekistan [N = 560], and
Nepal [N = 540]). Because similar results were obtained,
only results from the main analyses are shown. A p
value < .05 was considered to be significant. Statistical
Table 1 Number of patients included in GIPAP by country
in 2010
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package (StatCorp, TX, USA).
Results
A total of 4,946 patients in 47 institutions within 44
countries between 2003 and 2010 were included in the
study (Table 1). Of the 44 countries included, 20 were
least developed countries, including 2,266 (45.8%) out of
the total 4,946 patients. Institutional characteristics are
summarized in Table 2. The majority of institutions (80.8%)
were public/government and more than half (59.6%) were
in Africa. Although most of the institutions had specialized
human resources (hematologist or oncologist), institutional
technical competency was low, especially with respect to
the ability to perform bone marrow biopsy or aspiration.
One quarter of the institutions had research capabilities.
Patient characteristics are summarized in Table 3. Mean
patient age was 43.9 years, the sex ratio male: female was
1.3. Consistent with the predominance of African institu-
tions, the majority of the patients were in Africa. The main
diagnosis was CML in chronic phase. Average patient
follow-up was 2 years and 30% of cases were closed in 5
years. Of the 30% of cases closed in 5 years, 12% of closures
were due to clinical reasons, 7% due to loss of contact, 4%
due to patient death and 7% due to other reasons.
Enrollment rates were highly variable among different
institutions. The mean enrollment was 8.6 patients/year
(median: 2.7; SD: 14.1; IQR: 1.2-7.4). The multivariate
analysis using mixed models identified factors associated
with increased enrollment (Table 4). It appeared that the
WHO region was a strong predictor for the enrollment
capacity (Figure 1). Eastern European and SE Asian in-
stitutions showed the highest rates of enrolling patients
into GIPAP, while West African and Pacific institutions
showed the lowest rates. Contrasting results were found
with respect to institutional characteristics linked with
expertise. Specifically, the presence of ≥1 hematologist
or oncologist was associated with increased enrollment,
whereas bone aspiration capability and to a lesser extent
research ability were associated with lower enrollment
rates. Interestingly, the number of physicians working in
an individual institution was strongly associated with the
number of patients enrolled when the WHO region was
not considered, indicating that larger and better-staffed
hospitals had the highest enrollment rates. However, this
effect was no longer significant when WHO region was
included in the model, mostly because Eastern Europe
has predominantly larger, better-staffed hospitals com-
pared with other WHO regions.
Table 5 shows the results from multivariate analysis
assessing the patient activity as a proxy for survival. The
following patient factors were identified as being associ-
ated with decreased survival: age >55 years (HR = 1.42
[1.16; 1.73]; p = 0.001) and accelerated or blast crisis at








Eastern Europe 9 19.1
Pacifica 4 8.5
South East Asia 3 6.4
Specialized human resources*
Hematologist and oncologist 21 44.7
At least one hematologist or one oncologist 42 89.3
Research ability 12 25.5
Technical competency
Philadelphia or CD117 20 42.6
Bone marrow biopsy or aspiration 7 14.9
*At time institutions were approved for participation in GIPAP.
Table 4 Institutional factors associated with the number of
patients enrolled per year (multivariate linear mixed model)
All institutions (N = 4,946 patients)
β p-value CI 95%
Year 11.91 <10-4 [5.90; 17.93]
Interactions
Year*public 2.08 0.93 [-42.92; 47.08]
Year*hematologist or oncologist 6.12 0.02 [0.98; 11.27]
Year*research -2.59 0.13 [-5.94; 0.75]
Year*bone aspiration -8.78 <10-4 [-12.89; -4.66]
Year*Europe 0.00 (ref)
Year*SE Asia 3.04 0.34 [-3.24; 9.33]
Year*East Africa -0.59 0.78 [-4.86;3.67]
Year*West Africa -11.49 <10-4 [-15.53; -7.45]
Year*Pacific/America -14.66 <10-4 [-19.54; -9.77]
Results in bold are statistically significant at the 5% level.
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statistically not significant, gender was kept in the model
to account for sex-related variability. At the institutional
level, increased survival was found in institutions with
research capabilities (HR = 0.55 [0.35; 0.86]; p = 0.01) and
those with increasing enrollment ([2–5] patients/year:
HR = 0.69, p = 0.09; >5: HR = 0.48, p < 10-4; see Figure 2).Table 3 Characteristics of the patients (N = 4,946)
Patients (n = 4,946)
Age (mean, standard deviation) 43.9 (15.7)
> = 55 years (%) 25.4
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Duration of follow up
(month; mean, standard deviation)
25.8 (25.9)Although treatment at a public institution was associated
with a trend toward decreased survival, this trend did
not reach statistical significance (HR = 1.32 [0.95; 1.84];
p = 0.10). An institution’s technical competency (bone mar-
row biopsy or aspiration, detection of Ph + chromosome)
was not significantly associated with survival. A significant
interaction was found between having ≥1 hematologist or
oncologist and the impact of an accelerated form of CML at
initial diagnosis (HR= 0.43 [0.18; 0.99]; p = 0.05), suggesting
an attenuated impact. Finally, the introduction of the WHO
region into the model to control for national economics and
health system characteristics shared by countries within
WHO regions yielded similar results for the patient and in-
stitutional predictors (data not shown).
Discussion
Institutions in Eastern Europe and SE Asia had the
highest annual rates of GIPAP enrollment. The presence
of ≥1 hematologist or oncologist at the time GIPAP was
implemented was associated with increased enrollment.
The presence of a hematologist or oncologist at an insti-
tution likely drives increased GIPAP enrollment both by
drawing referrals from non-specialist physicians in the
area and by providing expertise in CML and GIST that
contributes to patients receiving standard of care treat-
ment with imatinib. These factors could be used to select
institutions for participation in other access programs in
order to facilitate rapid enrollment of eligible patients and
ensure traction of the program. Consideration of these
factors will be important in deciding whether to rollout
other access programs in select institutions or on a
broader basis in specific countries. Similarly, these factors
may help to identify the features of institutions that can
best adopt CML/GIST-targeted programs and those that
may need more time to become an entrenched part of the
Figure 1 Number of patients enrolled in GIPAP over time by WHO region: univariate analysis.
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assessed in our study but might play a role in explaining
the variability in patient enrollment across institutions.
These factors include a favorable reputation or the refer-
ence status of a center driving a high number of referrals,
which are often associated with a location in the capital
city of the country.
A number of patient and institutional factors were
associated with decreased survival, including age >55 years,
accelerated disease or blast crisis at time of diagnosis, and
to a lesser extent treatment at a public hospital. Of note,
treatment at an institution with high GIPAP enrollment
rates was associated with improved survival. This finding










≥1 hematologist or oncologist




Accelerated form * ≥1 hematologist or oncologist
Results in bold are statistically significant at the 5% level.
Other non-significant covariates entered in the model: gender, institution's technica
number of physicians, WHO region.and higher enrollment rates found in reference centers, but
might also be related to the positive impact in itself of the
growing clinical experience that high-enrolling facilities
gain in dealing with CML patients. The interaction between
the impact of an accelerated form of CML at initial diagno-
sis and the availability of specialist personnel demonstrates
the critical need for expertise in CML and GIST in order to
optimize patient outcomes. Hematologists and oncologists
are essential for ensuring that CML and GIST patients are
correctly diagnosed, receive appropriate therapy for their
indication, and are followed and monitored in order to de-
tect and manage adverse side effects of imatinib therapy.
Interestingly, this result was constantly found, even after
entering the WHO region into the model to somewhatnt and institutional factors in CML patients
Hazard ratio p-value CI 95%
1 (ref)
1.42 0.001 [1.16; 1.73]
1 (ref)
s 4.16 <10-4 [1.87; 9.25]
0.55 0.01 [0.35; 0.86]
1.32 0.10 [0.95; 1.84]
0.88 0.73 [0.44; 1.79]
1(ref)
0.69 0.09 [0.45; 1.07]
0.48 <10-4 [0.35; 0.67]
0.43 0.05 [0.18; 0.99]
l competency (bone marrow biopsy or aspiration, Ph + chromosome testing),
Figure 2 Active CML patients as a function of institutional enrollment capacity (Cox proportional hazards regression, adjusted for age,
gender, CML initial phase, public institution, presence of ≥ 1 hematologist or oncologist, research ability and technical competency).
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that could be nested at the supranational level and strongly
influence the results. These differences include the quality
and number of health care facilities, access to health care,
and availability of government or private insurance
programs. In order to achieve optimal health outcomes
for patients in GIPAP, greater emphasis should be
placed on institutional factors that improve survival,
regardless of the differences in health care infrastruc-
tures among different countries.
This study had several limitations. First, a number of
institutions included in this analysis had a small number
of patients included, which may limit the utility of their
datasets. Second, as previously described, the use of case
closure as a proxy for survival is an imprecise method
that may lead to incorrect assumptions about actual pa-
tient outcomes [11]. The ability to capture more precise
information about the reasons for patient drop-out or
case closure should improve our understanding of how
various patient and institutional factors impact health
outcomes for patients in GIPAP. Additionally, the study
looked only at institutional factors that could affect
enrollment rates. Consequently, the study does not take
into account external factors, such as access to health fa-
cilities (i.e. hospitals coverage), national health policies,
awareness of GIPAP, number of institutions participating
in GIPAP and cultural factors, all of which could impact
the number of patients seeking care for CML or GIST
or the willingness of patients to participate in GIPAP.
Another limitation arises from the use of raw enrollment
rate as a metric for institutional success regardless of
factors such as the actual number of patients the institution
can reach. A small hospital would be expected to have a
smaller reach and refer more patients for treatment else-
where than a large health center that attracts more patients
and receives more referrals. However, adjusting enrollmentrates based on the number of physicians at an institution
may account for part of the difference in reach between
large and small facilities, and the stratification criterion to
define high- or low-enrolling programs was only 3 patients/
year (median rate among all institutions), which constitutes
a low threshold reachable by most institutions, regardless
of their size. Finally, our results were derived from a subset
of countries and institutions within GIPAP, and did not in-
clude countries in which Novartis directly managed GIPAP
programs. It is thus likely that our findings are not fully
representative of all GIPAP programs, and could inadvert-
ently highlight peculiar associations between institutional
factors and the outcomes assessed. Further research should
be conducted to confirm our results in other countries.
Additional data on the impact of patient and institu-
tional characteristics on patient outcomes continue to be
collected. Further evaluation of this growing body of
data should help to identify factors that improve outcomes
for patients with CML or GIST. Incorporation of findings
of such analyses into the structure of GIPAP may help to
increase the program’s effectiveness and may help improve
outcomes for patients participating in the program. Identi-
fication of institutional characteristics associated with im-
proved patient outcomes may enable criteria that could be
used to select institutions for GIPAP participation. The
ability to select institutions most able to improve patient
outcomes would likely increase the success of an access
program. This may be especially important when drug ac-
cess programs are initially implemented, as early success
should help them to gain traction and could facilitate their
rapid and effective implementation.
The identification of infrastructure factors that con-
tribute to the gap between the most and least successful
programs may help lower-performing institutions to
enroll more eligible patients into GIPAP and provide pa-
tients in the program with better quality treatment. In
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abilities was associated with improved patient survival.
However, such capabilities were available at only 26%
of the 47 institutions evaluated. Institutional research
capacity is likely a marker of scientific expertise, which
is often found only in the regional referral hospital, rather
than being a cause of increased survival. Patient outcomes
at hospitals without research capabilities might be im-
proved by having referral hospitals lend their scientific
expertise to smaller institutions. Institutional perform-
ance may also be improved by expanding access to
diagnostic tests, which could help to identify additional
patients eligible for GIPAP. Similarly, better training of
health care workers and strengthening of the referral
system for patients diagnosed with CML or GIST may
increase the opportunity for these patients to receive
optimized treatment for their disease.
While GIPAP helps improve access to imatinib, the
program is not designed to support these types of
infrastructure improvements. Improving the skills of
health care personnel and increasing the availability of
diagnostic resources will require additional funding,
training, and logistical support. Establishment of this
infrastructure will likely require dedicated resources
from and cooperation among institutions, their govern-
ments, NGOs, and manufacturers of diagnostic and
research equipment. A multi-sector approach is neces-
sary to improve access to cancer care in general and
CML/GIST in particular. Support of such endeavors
may provide benefit beyond the treatment of CML or
GIST by improving and expanding the services available
to patients with a variety of diseases.
Other programs designed to increase access to cancer
medications should also consider the experiences of
individual countries that have participated in GIPAP to
date. Challenges implementing GIPAP have been reported,
including the low priority assigned to cancer by many de-
veloping countries, the limited healthcare infrastructure
and cultural and education differences [22]. In addition,
the diagnostic tests required for entry into GIPAP are not
available in most of the least developed countries. For ex-
ample, in Kenya blood samples are sent out of the country
for analysis. This puts the costs of entry tests outside the
financial reach of many patients who might otherwise be
eligible for the program [23]. Other challenges identified
in Kenya were patients’ lack of resources to visit clinics or
pickup medication and the cost of tests required to apply
for second-line therapy in patients who develop resistance
to imatinib [23]. These challenges are likely to occur in
other low-income countries. Experiences in participating
countries indicate that patient and physician education,
patient monitoring and follow-up and integration with
existing health care infrastructure are critical to the suc-
cess of GIPAP [22].Beyond increasing access to imatinib, the GIPAP
model might also be applicable to other drugs that are
indicated for CML and GIST. For example, nilotinib has
been shown to provide better efficacy than imatinib in
patients with newly diagnosed CML in the chronic phase
[24]. Other studies have shown that nilotinib provides clin-
ical benefit as a first-line therapy in patients with GIST
[25]. Nilotinib could be an important therapeutic alterna-
tive for patients who are resistant or intolerant to imatinib
and second-line sunitinib and who typically have poor
prognoses and fewer treatment options [26]. Expanding
access to nilotinib would further improve outcomes for
CML and GIST patients in low- and middle-income
countries [24,27,28].
Insights gained through further evaluation of GIPAP
and the factors underpinning its success may support
development of other donation and cost-sharing models
that expand access to medications for the treatment of
other chronic diseases in addition to cancer. Identifying
sustainable methods for providing medication for chronic
diseases is rising in importance given the substantial mor-
bidity and mortality associated with cardiovascular disease,
diabetes and cancer in the developing world [29]. Although
GIPAP is a full donation program, the factors associated
with institutional success and improved patient outcomes
may help to inform the development of other, more eco-
nomically sustainable models for increasing access to medi-
cines for cancer and other chronic diseases.
Conclusion
In the context of GIPAP, treatment at an institution with
high enrollment rates, local medical expertise and re-
search capabilities are associated with improved patient
survival, regardless of the patient’s age or initial stage of
the disease. Use of these findings to optimize GIPAP
should help improve access to care and treatment out-
comes for patients with CML or GIST.
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